---
title: "藥捷安康核心產品替恩戈替尼發表探索性臨牀結果"
description: "藥捷安康宣佈其核心產品替恩戈替尼在美國進行的膽管癌探索性臨牀 2 期結果發表在《柳葉刀，胃腸病和肝病學》。研究顯示，替恩戈替尼可克服 FGFR2 融合陽性膽管癌患者對 FGFR 抑制劑的耐藥性，並在其他 FGFR 基因改變的患者中顯示抗腫瘤活性。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270025011.md"
published_at: "2025-12-17T14:13:56.000Z"
---

# 藥捷安康核心產品替恩戈替尼發表探索性臨牀結果

> 藥捷安康宣佈其核心產品替恩戈替尼在美國進行的膽管癌探索性臨牀 2 期結果發表在《柳葉刀，胃腸病和肝病學》。研究顯示，替恩戈替尼可克服 FGFR2 融合陽性膽管癌患者對 FGFR 抑制劑的耐藥性，並在其他 FGFR 基因改變的患者中顯示抗腫瘤活性。

藥捷安康－B(02617.HK) 公佈，近日，公司核心產品替恩戈替尼在美國開展的針對膽管癌的探索性臨牀 2 期結果在《柳葉刀，胃腸病和肝病學》發表。替恩戈替尼可克服 FGFR2 融合陽性膽管癌患者對 FGFR 抑制劑的獲得性耐藥，並在其他 FGFR 基因改變的膽管癌患者中顯示出抗腫瘤活性。

在這項 2 期、開放標籤、多中心研究中，符合條件的膽管癌患者包括攜帶 FGFR2 融合且對 FGFR 抑制劑存在原發性或獲得性耐藥的患者，或存在其他 FGFR 基因改變的患者，以及 FGFR 野生型患者。

### Related Stocks

- [02617.HK - 藥捷安康-B](https://longbridge.com/zh-HK/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Extensively Drug-resistant Salmonella Outbreak Linked To Moringa Powder Capsules | The CDC has reported a multi-state outbreak of extensively drug-resistant Salmonella linked to Rosabella brand moringa p | [Link](https://longbridge.com/zh-HK/news/276049869.md) |
| Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial | Abbisko Cayman Limited has dosed the first U.S. patient in a global Phase I trial of irpagratinib, an FGFR4 inhibitor fo | [Link](https://longbridge.com/zh-HK/news/275528457.md) |
| 13:03 ETBelay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) | Belay Diagnostics has announced the validation of its Summit™ 2.0 Comprehensive Genomic Profile assay for cerebrospinal  | [Link](https://longbridge.com/zh-HK/news/276259162.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。